DAVITA INC. (DVA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.94%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.94% | Share-based compensation / revenue. Period ending 2026-06-30. $131.57M ÷ $14.01B × 100 ≈ 0.94% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 14.01B USD | |
| Stock-based compensation | 131.57M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.13B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $14.01B | $131.57M | $2.13B | (m) | (m) | 0.94% | (m) | (m) |
| 2026-03-31 | (m) | $13.84B | $138.35M | $2.09B | (m) | (m) | 1.00% | (m) | (m) |
| 2025-12-31 | (m) | $13.64B | $139.95M | $2.04B | (m) | (m) | 1.03% | (m) | (m) |
| 2025-09-30 | (m) | $13.32B | $128.96M | $2.05B | (m) | (m) | 0.97% | (m) | (m) |
| 2025-06-30 | (m) | $13.16B | $116.52M | $2.08B | (m) | (m) | 0.89% | (m) | (m) |
| 2025-03-31 | (m) | $12.97B | $108.00M | $2.05B | (m) | (m) | 0.83% | (m) | (m) |
| 2024-12-31 | (m) | $12.82B | $102.79M | $2.09B | (m) | (m) | 0.80% | (m) | (m) |
| 2024-09-30 | (m) | $12.67B | $105.45M | $1.92B | (m) | (m) | 0.83% | (m) | (m) |
| 2024-06-30 | (m) | $12.52B | $106.01M | $1.88B | (m) | (m) | 0.85% | (m) | (m) |
| 2024-03-31 | (m) | $12.34B | $111.54M | $1.77B | (m) | (m) | 0.90% | (m) | (m) |
| 2023-12-31 | (m) | $12.14B | $112.38M | $1.60B | (m) | (m) | 0.93% | (m) | (m) |
| 2023-09-30 | (m) | $11.91B | $99.84M | $1.47B | (m) | (m) | 0.84% | (m) | (m) |
| 2023-06-30 | (m) | $11.74B | $100.52M | $1.28B | (m) | (m) | 0.86% | (m) | (m) |
| 2023-03-31 | (m) | $11.67B | $95.90M | $1.31B | (m) | (m) | 0.82% | (m) | (m) |
| 2022-12-31 | (m) | $11.61B | $95.43M | $1.34B | (m) | (m) | 0.82% | (m) | (m) |
| 2022-09-30 | (m) | $11.64B | $104.22M | $1.47B | (m) | (m) | 0.90% | (m) | (m) |
| 2022-06-30 | (m) | $11.63B | $100.60M | $1.64B | (m) | (m) | 0.87% | (m) | (m) |
| 2022-03-31 | (m) | $11.62B | $103.52M | $1.69B | (m) | (m) | 0.89% | (m) | (m) |
| 2021-12-31 | (m) | $11.62B | $102.21M | $1.80B | (m) | (m) | 0.88% | (m) | (m) |
| 2021-09-30 | (m) | $11.58B | $100.14M | $1.79B | (m) | (m) | 0.86% | (m) | (m) |
| 2021-06-30 | (m) | $11.57B | $101.05M | $1.75B | (m) | (m) | 0.87% | (m) | (m) |
| 2021-03-31 | (m) | $11.53B | $95.18M | $1.67B | (m) | (m) | 0.83% | (m) | (m) |
| 2020-12-31 | (m) | $11.55B | $91.46M | $1.69B | (m) | (m) | 0.79% | (m) | (m) |
| 2020-09-30 | (m) | $11.54B | $87.26M | $1.78B | (m) | (m) | 0.76% | (m) | (m) |
| 2020-06-30 | (m) | $11.52B | $80.93M | $1.72B | (m) | (m) | 0.70% | (m) | (m) |
| 2020-03-31 | (m) | $11.49B | $75.61M | $1.77B | (m) | (m) | 0.66% | (m) | (m) |
| 2019-12-31 | (m) | $11.39B | $67.85M | $1.64B | (m) | (m) | 0.60% | (m) | (m) |
| 2019-09-30 | (m) | $11.31B | $61.27M | $1.57B | (m) | (m) | 0.54% | (m) | (m) |
| 2019-06-30 | (m) | $11.25B | $82.25M | $1.48B | (m) | (m) | 0.73% | (m) | (m) |
| 2019-03-31 | (m) | $11.30B | $75.49M | $1.46B | (m) | (m) | 0.67% | (m) | (m) |
| 2018-12-31 | (m) | $11.40B | $73.06M | $1.53B | (m) | (m) | 0.64% | (m) | (m) |
| 2018-09-30 | (m) | (m) | $66.22M | $1.29B | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $37.45M | $1.39B | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $35.18M | $1.35B | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $35.09M | $1.81B | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $37.00M | $1.46B | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $32.13M | $2.47B | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $34.84M | $2.42B | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $38.34M | $1.89B | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $43.69M | $1.76B | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $52.08M | $1.45B | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $57.00M | $1.60B | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $56.66M | $1.17B | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $55.21M | $1.38B | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $55.34M | $1.31B | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $54.43M | $1.31B | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $56.74M | $1.82B | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $57.23M | $1.85B | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $57.43M | $1.79B | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $59.05M | $1.82B | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $60.00M | $1.55B | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $57.62M | $1.45B | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $53.31M | $1.42B | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $48.85M | $1.14B | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $45.38M | $1.30B | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $47.18M | $1.24B | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $50.00M | $1.22B | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $51.55M | $1.22B | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $48.72M | $1.13B | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $48.45M | $1.06B | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $46.21M | $994.60M | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $45.03M | $989.91M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $45.55M | $997.03M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $44.06M | $980.33M | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $44.41M | $968.74M | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $43.65M | $962.33M | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $44.42M | $940.27M | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $41.23M | $869.10M | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $34.15M | $908.91M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |